The NAD+ Debate: Promise vs. Proof in Longevity Science

The compound nicotinamide adenine dinucleotide (NAD+) has captured the attention of both longevity researchers and the wellness industry. While animal studies have shown promising effects on mitochondrial health and aging, human trials have produced mixed results.

What We Know

NAD+ levels naturally decline with age, a process that may contribute to age-related diseases. This biological fact has fueled intense interest in finding ways to restore youthful levels.

Animal studies—primarily in rodents and mice—have demonstrated improvements in:

• Mitochondrial health
• Strength and exercise performance
• Reduced metabolic abnormalities
• Decreased inflammation

"The data in humans is 'iffy' regarding significant benefits."
— Dr. Samuel Klein, Washington University School of Medicine

The Human Trial Reality

Human trials of NAD+ precursors—specifically nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN)—have shown safety and successfully increased NAD+ levels in the blood. However, meaningful health benefits in large human studies remain unestablished.

The Supplement Problem

• Oral NAD+ supplements are widely marketed, despite evidence that NAD+ is poorly absorbed orally
• Clinical studies instead use precursor pills (NR, NMN)
• Supplement quality varies significantly, and labels may not match actual contents

The IV Infusion Question

Wellness clinics offer IV NAD+ infusions at prices ranging from $200 to $1,000 per session. Yet there is almost no published data to support their use. One pilot study found that infusions were inefficient at raising cellular NAD+ levels and caused notable side effects, including abdominal cramping, nausea, and vomiting.

Expert Perspectives

"Data remain preliminary until replicated in large human trials."
— Christopher Martens, Delaware Center for Cognitive Aging Research

"Health benefits of augmenting NAD+ are not yet established in large human studies."
— Dr. Shalender Bhasin, Boston Pepper Aging Research Center

Rachel Pojednic (Restore Hyper Wellness / Stanford University) strikes a more tempered note: early clinical trials are ongoing, and NAD+ should not be dismissed—but the science is still in early stages.

The Unknowns

Safety Concerns

Long-term safety is unknown. Some animal studies have raised concerns about possible tumor growth, though this has not been observed in human studies so far.

Known Risks

• IV infusions are associated with unpleasant gastrointestinal side effects
• The high cost of IV therapy comes with no proven benefit

Bottom Line

The science behind NAD+ supplementation remains promising but unproven in humans. Until large, rigorous trials establish both efficacy and long-term safety, consumers should approach NAD+ products—especially expensive IV treatments—with caution.